Evaluation of Tirzepatide as an Adjunct to Buprenorphine for the Treatment of Opioid Use Disorder
NCT06651177
Not Yet Recruiting
The primary objective of this research study is to evaluate the effect of tirzepatide, relative to placebo, as an adjunct to BUP on retention, substance use, and sleep outcomes in individuals with OUD.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/11/2025
Locations: Marshall Health, Huntington, West Virginia +1 locations
Conditions: Opioid Use Disorder, Opioid Use Disorder, Moderate, Opioid Use Disorder, Severe
Register for Updates
A Study of Tirzepatide (LY3298176) on the Reduction on Morbidity and Mortality in Adults With Obesity
NCT05556512
Active Not Recruiting
This study will investigate the effect of tirzepatide on the reduction of morbidity and mortality in adults living with obesity and provide additional evidence for the potential clinical benefits of tirzepatide in this population.
Gender:
ALL
Ages:
40 years and above
Trial Updated:
07/01/2025
Locations: IMA Clinical Research, Morgantown, West Virginia
Conditions: Obesity, Overweight
Register for Updates
Ixekizumab Concomitantly Administered With Tirzepatide in Adults With Psoriatic Arthritis and Obesity or Overweight
NCT06588296
Active Not Recruiting
The main purpose of this study is to demonstrate that when participants with psoriatic arthritis and obesity or overweight in the presence of at least 1 weight-related comorbid condition receive ixekizumab and tirzepatide concomitantly administered, participants see improvement in their psoriatic arthritis and achieve weight reduction compared to when receiving ixekizumab. Participation in this study includes up to 12 visits and could last up to 61 weeks including screening, open label treatmen... Read More
Gender:
ALL
Ages:
Between 18 years and 80 years
Trial Updated:
07/01/2025
Locations: Rheumatology & Pulmonary Clinic, Beckley, West Virginia
Conditions: Psoriatic Arthritis, Obesity
Register for Updates